Overview

A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides

Status:
Completed
Trial end date:
2016-04-26
Target enrollment:
0
Participant gender:
All
Summary
This is a safety and efficacy study of onabotulinumtoxinA in subjects with forehead and glabellar facial rhytides (frown lines).
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Allergan
Treatments:
abobotulinumtoxinA
Botulinum Toxins
Botulinum Toxins, Type A
incobotulinumtoxinA
onabotulinumtoxinA
Criteria
Inclusion Criteria:

- Moderate to severe forehead and glabellar lines

- Willing to have facial photos taken

Exclusion Criteria:

- Prior exposure to botulinum toxin of any serotype for any indication

- Anticipated need for treatment with botulinum toxin of any serotype for any indication
during the study, other than study treatment

- Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, or amyotrophic lateral
sclerosis

- Any facial resurfacing laser or light treatment, microdermabrasion, or superficial
peels in the past 3 months

- Any medium depth or deep depth facial chemical peels; facial skin resurfacing; or
permanent facial make-up in the past 6 months

- Any nonpermanent soft tissue fillers, or treatment with oral retinoids in the past
year

- Prior face lift, thread lift, eyebrow lift, or related procedures (eg, eyelid and/or
eyebrow surgery)

- Prior facial treatment with permanent soft tissue fillers, synthetic implants (eg,
Gore-Tex®), and/or fat transplantation